RT Journal Article
SR Electronic
T1 Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.31.20182428
DO 10.1101/2020.08.31.20182428
A1 Rubio-Rivas, Manuel
A1 Ronda, Mar
A1 Padulles, Ariadna
A1 Mitjavila, Francesca
A1 Riera-Mestre, Antoni
A1 García-Forero, Carlos
A1 Iriarte, Adriana
A1 Mora, Jose M.
A1 Padulles, Nuria
A1 Gonzalez, Monica
A1 Solanich, Xavier
A1 Gasa, Merce
A1 Suarez, Guillermo
A1 Sabater, Joan
A1 Perez-Fernandez, Xose L.
A1 Santacana, Eugenia
A1 Leiva, Elisabet
A1 Ariza-Sole, Albert
A1 Dallaglio, Paolo D.
A1 Quero, Maria
A1 Soriano, Antonio
A1 Pasqualetto, Alberto
A1 Koo, Maylin
A1 Esteve, Virginia
A1 Antoli, Arnau
A1 Moreno, Rafael
A1 Yun, Sergi
A1 Cerda, Pau
A1 Llaberia, Mariona
A1 Formiga, Francesc
A1 Fanlo, Marta
A1 Montero, Abelardo
A1 Chivite, David
A1 Capdevila, Olga
A1 Bolao, Ferran
A1 Pinto, Xavier
A1 Llop, Josep
A1 Sabate, Antoni
A1 Guardiola, Jordi
A1 Cruzado, Josep M.
A1 Comin-Colet, Josep
A1 Santos, Salud
A1 Jodar, Ramon
A1 Corbella, Xavier
YR 2020
UL http://medrxiv.org/content/early/2020/09/01/2020.08.31.20182428.abstract
AB Introduction On the basis of the preliminary report from the RECOVERY trial, the use of dexamethasone or alternative corticosteroids (CS) is currently recommended in severe COVID-19 patients requiring supplemental oxygen. However, last updated recommendations have not taken a position either for or against the use of other immunomodulators such as tocilizumab (TCZ), with or without CS, since results are still limited.Methods From March 17 to April 7, 2020, a real-world observational retrospective analysis was conducted at our 750-bed university hospital to study the characteristics and risk factors for mortality in patients with severe COVID-19 treated with TCZ +/-CS, in addition to standard of care (SOC). Data were obtained from routine clinical practice, stored in electronic medical records. The main outcome was all-cause in-hospital mortality.Results A total of 1,092 COVID-19 patients were admitted during the study period. Of them, 186 (17%) were treated with TCZ, of which 129 (87.8%) in combination with CS. Of the total 186, 155 (83.3 %) patients were receiving non-invasive ventilation when TCZ +/-CS was initiated. Mean time from symptoms onset and hospital admission to TCZ use was 12 (± 4.3) and 4.3 days (± 3.4), respectively. Overall, 147 (79%) survived and 39 (21%) died. By multivariate analysis, mortality was associated with older age (HR=1.09, p<0.001), chronic heart failure (HR=4.4, p=0.003), and chronic liver disease (HR=4.69, p=0.004). The use of CS, in combination with TCZ, was the main protective factor against mortality (HR=0.26, p<0.001) in such severe COVID-19 patients receiving TCZ. No serious superinfections were observed after a 30-day follow-up.Conclusions In severe COVID-19 patients receiving TCZ due to systemic host-immune inflammatory response syndrome, the use of CS in addition to TCZ therapy, showed beneficial effect in preventing in-hospital mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding or sponsorship was received for this study or publication of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study received the ethical approval by the Research Ethics Committee of Bellvitge University Hospital (PR145/20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.